Evidence map›Paper›PMID 35719329›Full record

ArticleFrontiers in cellular and infection microbiology2022

Validation of Serological Methods for COVID-19 and Retrospective Screening of Health Employees and Visitors to the São Paulo University Hospital, Brazil.

Robert Andreata-Santos, Rafael Rahal Guaragna Machado, Rúbens Prince Dos Santos Alves, Natiely Silva Sales, Camila Pereira Soares, Karine Bitencourt Rodrigues, Mariângela Oliveira Silva, Marianna Teixeira de Pinho Favaro, Mônica Josiane Rodrigues-Jesus, Márcio Massao Yamamoto and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Robert Andreata-SantosVaccine Development Laboratory, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Rafael Rahal Guaragna MachadoClinical and Molecular Virology Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Rúbens Prince Dos Santos AlvesVaccine Development Laboratory, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Natiely Silva SalesVaccine Development Laboratory, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Camila Pereira SoaresClinical and Molecular Virology Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Karine Bitencourt RodriguesVaccine Development Laboratory, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Mariângela Oliveira SilvaVaccine Development Laboratory, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Marianna Teixeira de Pinho FavaroVaccine Development Laboratory, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Mônica Josiane Rodrigues-JesusVaccine Development Laboratory, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Márcio Massao YamamotoDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Juliana Bannwart de AndradeSchool of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Ricardo Ambrósio FockSchool of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Paulo Francisco Ramos MargaridoSchool of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Cristiane Rodrigues Guzzo CarvalhoMolecular and Structural Biology, Secretion Systems and c-di-GMP Signalling Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Silvia Beatriz BoscardinDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Edison Luiz DurigonClinical and Molecular Virology Laboratory, Microbiology Department, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Luís C S FerreiraVaccine Development Laboratory, Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reliable serological tests for the detection of SARS-CoV-2 antibodies among infected or vaccinated individuals are important for epidemiological and clinical studies. Low-cost approaches easily adaptable to high throughput screenings, such as Enzyme-Linked Immunosorbent Assays (ELISA) or electrochemiluminescence immunoassay (ECLIA), can be readily validated using different SARS-CoV-2 antigens. A total of 1,119 serum samples collected between March and July of 2020 from health employees and visitors to the University Hospital at the University of São Paulo were screened with the Elecsys

Indexed as

COVID-19Antibodies, ViralBrazilClinical Laboratory TechniquesHospitalsHumansRetrospective StudiesSARS-CoV-2Sensitivity and SpecificityAntibodies, ViralECLIAELISAhealth employeesSARS-CoV-2serologysurveillance

Identifiers

PMID35719329
PMCPMC9202673
OpenAlexW4281713879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.